Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

J Am Acad Dermatol. 2022 Jan;86(1):249-252. doi: 10.1016/j.jaad.2021.09.016. Epub 2021 Sep 16.
No abstract available

Keywords: COVID; COVID-19; biologics; comorbidities; hidradenitis suppurativa; pandemic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Therapy / adverse effects*
  • COVID-19* / diagnosis
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Registries
  • Severity of Illness Index